FDA Approves Merck's IDVYNSO for HIV-1 Treatment in Adults
Merck announced that the U.S. Food and Drug Administration (FDA) has approved IDVYNSO, a new two-drug single-tablet regimen for the treatment of HIV-1 infection in adults. This regimen combines 100 mg doravirine and 0.25 mg islatravir and is intended for patients who are virologically suppressed with no history of virologic treatment failure. IDVYNSO is contraindicated with certain drugs, including strong cytochrome P450 enzyme inducers and lamivudine or emtricitabine, as these may decrease its effectiveness. The approval is based on data from Phase 3 trials showing non-inferior efficacy compared to existing three-drug regimens. The regimen is set to be available in pharmacies after May 11. 
